Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting

OXFORD, England, May 9, 2022 /PRNewswire/ -- Enara Bio, a biotechnology company advancing novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific

Related Keywords

Sweden ,Eleanor Perkin ,Frazer Hall ,Thierry Schmidlin ,Enara Bio ,Nicola Ternette ,Prnewswire Enara Bio ,Kostenloser Wertpapierhandel ,Tony Purcell ,Jamie Rossjohn ,Kevin Pojasek ,Monash University ,Sv Health Investors ,University Of Oxford ,European Molecular Biology Organization ,Boehringer Ingelheim ,Monash Biomedicine Discovery Institute ,Cardiff University ,Head Of Research At Enara Bio ,University Of Oxford Nuffield Department Medicine ,Johns Hopkins School Of Medicine ,Francis Crick Institute ,Molecular Biology Organization ,Nuffield Department ,Vice President ,Dark Antigens ,Dark Antigen ,United Kingdom Based ,Johns Hopkins School ,Mark Swallow ,Menara ,Collaborators ,Present ,Progress ,Cowards ,Developing ,Argeted ,Fell ,Therapies ,12th ,Nternational ,Mambo ,Meeting ,